Lipella Pharmaceuticals Inc. (LIPO)
Automate Your Wheel Strategy on LIPO
With Tiblio's Option Bot, you can configure your own wheel strategy including LIPO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LIPO
- Rev/Share 63.0981
- Book/Share 1983.2731
- PB 0.0015
- Debt/Equity 0.0059
- CurrentRatio 6.2089
- ROIC -0.3245
- MktCap 13156478.0
- FreeCF/Share -694.6157
- PFCF -0.0092
- PE -0.0046
- Debt/Assets 0.0049
- DivYield 0
- ROE -1.2833
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025
Published: April 22, 2025 by: MCAP MediaWire
Sentiment: Neutral
Listen: PITTSBURGH, April 22, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced positive topline results from the second cohort (0.
Read More
Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement PITTSBURGH, April 22, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced positive topline results from the second cohort (0.50 mg) of its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10, for the treatment of oral lichen planus …
Read More
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast
Published: March 31, 2025 by: MCAP MediaWire
Sentiment: Neutral
Episode titled “From Medicine to Biotech Innovation” now available PITTSBURGH, March 31, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced that Co-Founder and Chief Medical Officer Dr.
Read More
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast
Published: March 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
PITTSBURGH, March 31, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced that Co-Founder and Chief Medical Officer Dr. Michael Chancellor is featured in the latest episode of The Pharmaverse Podcast, hosted by pharmaceutical industry executive recruiter Michael Pietrack. The episode, titled “From Medicine to Biotech Innovation,” offers an inside look at Dr. Chancellor's journey from clinical medicine to biotech leadership.
Read More
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
New York, NY, March 04, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of a $3,788,000 private placement for Lipella Pharmaceuticals Inc. (Nasdaq: LIPO). Spartan Capital Securities, LLC acted as the sole placement agent in this private offering.
Read More
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
Published: February 11, 2025 by: MCAP MediaWire
Sentiment: Neutral
PITTSBURGH, Feb. 11, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
Read More
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse Multicenter Phase 2a Trial Advancing to Higher Treatment Dose with Recruitment Expected to Conclude the First Half of 2025 Lipella Leadership to Present Findings at BIO CEO & Investor Conference on Tuesday, February 11, 2025, at 2:30 p.m. EST PITTSBURGH, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today shared topline analysis of its …
Read More
About Lipella Pharmaceuticals Inc. (LIPO)
- IPO Date 2022-12-19
- Website https://www.lipella.com
- Industry Biotechnology
- CEO Dr. Jonathan Kaufman M.B.A., Ph.D.
- Employees 5